JP2011500718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500718A5 JP2011500718A5 JP2010530124A JP2010530124A JP2011500718A5 JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5 JP 2010530124 A JP2010530124 A JP 2010530124A JP 2010530124 A JP2010530124 A JP 2010530124A JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5
- Authority
- JP
- Japan
- Prior art keywords
- mva
- antigen
- polypeptide
- pap
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 61
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 229940123237 Taxane Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 13
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 claims description 12
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 claims description 12
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 230000002476 tumorcidal effect Effects 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 claims description 9
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000037452 priming Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 108091029795 Intergenic region Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims description 2
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96089307P | 2007-10-18 | 2007-10-18 | |
| US60/960,893 | 2007-10-18 | ||
| PCT/US2008/080229 WO2009052328A1 (en) | 2007-10-18 | 2008-10-16 | Use of mva to treat prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500718A JP2011500718A (ja) | 2011-01-06 |
| JP2011500718A5 true JP2011500718A5 (https=) | 2011-10-20 |
| JP5669581B2 JP5669581B2 (ja) | 2015-02-12 |
Family
ID=40342626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530124A Expired - Fee Related JP5669581B2 (ja) | 2007-10-18 | 2008-10-16 | 前立腺癌を処置するためのｍｖａの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7867483B2 (https=) |
| EP (1) | EP2207564B1 (https=) |
| JP (1) | JP5669581B2 (https=) |
| KR (2) | KR101648087B1 (https=) |
| CN (1) | CN101888853B (https=) |
| AU (1) | AU2008312444B2 (https=) |
| CA (1) | CA2702586C (https=) |
| DK (1) | DK2207564T3 (https=) |
| ES (1) | ES2608604T3 (https=) |
| IL (1) | IL204541A (https=) |
| NZ (2) | NZ601827A (https=) |
| RU (1) | RU2499606C2 (https=) |
| WO (1) | WO2009052328A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| PL212047B1 (pl) * | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| NZ601827A (en) * | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| GB2484058A (en) * | 2009-12-01 | 2012-04-04 | Uni Konstanz | Prostate cancer DNA vaccine |
| CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| JP6312141B2 (ja) | 2012-03-30 | 2018-04-18 | 国立大学法人京都大学 | 前立腺がん検査用尿中バイオマーカー |
| JP2016535989A (ja) * | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
| CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| AU2016332352A1 (en) * | 2015-10-02 | 2018-04-12 | Memorial Sloan-Kettering Cancer Center | Small molecules blocking histone reader domains |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| CN108883203A (zh) | 2016-02-12 | 2018-11-23 | 麦迪逊疫苗公司 | 癌症疗法 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| WO2017188287A1 (ja) * | 2016-04-26 | 2017-11-02 | 大日本住友製薬株式会社 | 置換プリン誘導体 |
| CA3026342A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| HUE061619T2 (hu) | 2016-06-03 | 2023-07-28 | Regeneron Pharma | Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| CN106084027A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| JP2022536122A (ja) * | 2019-06-07 | 2022-08-12 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 腫瘍関連抗原特異的ｔ細胞応答 |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| EP4135757A1 (en) * | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| US12295997B2 (en) * | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993001831A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Induction of cytotoxic t-lymphocyte responses |
| ATE303160T1 (de) * | 1993-08-11 | 2005-09-15 | Jenner Technologies | Impfstoff gegen prostatakrebs |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| WO1998004689A1 (en) * | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| IL141868A0 (en) | 1998-10-05 | 2002-03-10 | M & E Biotech As | Novel methods for therapeutic vaccination |
| EP1137792B9 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| AU2003219983A1 (en) * | 2002-03-01 | 2003-09-16 | Applied Immune Technologies | Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens |
| CN102703393A (zh) * | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| US20070196346A1 (en) * | 2003-08-21 | 2007-08-23 | Brown Michael P | Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer |
| BRPI0401465A (pt) | 2004-04-20 | 2006-02-21 | Embria Informatica Ltda | sistema para administrar interações entre usuários e aplicações de software em um ambiente web |
| NZ601827A (en) * | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
-
2008
- 2008-10-16 NZ NZ601827A patent/NZ601827A/en not_active IP Right Cessation
- 2008-10-16 KR KR1020107010873A patent/KR101648087B1/ko not_active Expired - Fee Related
- 2008-10-16 RU RU2010115220/15A patent/RU2499606C2/ru not_active IP Right Cessation
- 2008-10-16 KR KR1020167013629A patent/KR20160065985A/ko not_active Ceased
- 2008-10-16 WO PCT/US2008/080229 patent/WO2009052328A1/en not_active Ceased
- 2008-10-16 US US12/253,094 patent/US7867483B2/en not_active Expired - Fee Related
- 2008-10-16 ES ES08839145.3T patent/ES2608604T3/es active Active
- 2008-10-16 JP JP2010530124A patent/JP5669581B2/ja not_active Expired - Fee Related
- 2008-10-16 CA CA2702586A patent/CA2702586C/en not_active Expired - Fee Related
- 2008-10-16 AU AU2008312444A patent/AU2008312444B2/en not_active Ceased
- 2008-10-16 NZ NZ584042A patent/NZ584042A/xx not_active IP Right Cessation
- 2008-10-16 EP EP08839145.3A patent/EP2207564B1/en not_active Not-in-force
- 2008-10-16 DK DK08839145.3T patent/DK2207564T3/en active
- 2008-10-16 CN CN2008801193517A patent/CN101888853B/zh not_active Expired - Fee Related
-
2010
- 2010-03-16 IL IL204541A patent/IL204541A/en active IP Right Grant
- 2010-08-30 US US12/871,017 patent/US8377688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500718A5 (https=) | ||
| JP6945301B2 (ja) | Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン | |
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| Gómez et al. | Clinical applications of attenuated MVA poxvirus strain | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| EP2958994B1 (en) | Vaccine composition | |
| RU2010115220A (ru) | Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты | |
| EP2408473B1 (en) | Vaccination methods | |
| Webster et al. | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | |
| WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| US8734806B2 (en) | Immunogenic composition and use thereof | |
| Bubenik et al. | Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. | |
| JP2018517419A5 (https=) | ||
| US12246038B2 (en) | Compositions for inducing an immune response | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| JP2014139185A5 (https=) | ||
| Chen et al. | Optimisation of prime–boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine | |
| Marcos-Villar et al. | Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| Iampietro et al. | Immunogenicity and cross-reactivity of rhesus adenoviral vectors | |
| Wang et al. | Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge | |
| Wan et al. | As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス |